All news

A strong showing of Montpellier biotech in Boston

Information updated on 12/07/18

A delegation from Montpellier Méditerranée Métropole went to Boston (USA) on June 4-7 for the BIO International Convention.

Photo Bio Boston ©MMM
With sponsorship from Montpellier Health Capital, the delegation accompanied ten Montpellier startups to the world-class business convention for the Pharma/Biotech industry. A springboard for innovative companies in the medical field.

Chantal Marion, vice-president of Montpellier Métropole accompanied a delegation of ten startup companies to the BIO International Convention in Boston, one of the world’s leading biotechnology hubs, alongside the Eurobiomed competitiveness cluster. The goal was to promote the international excellence of the local health sector and companies. BIO is a key strategic opportunity for Montpellier area companies such as Amylgen, Biodol Therapeutics, CILcare, Ciloa, Deinove, Expernova, Histalim, MedinCell, Oxeltis, and Sensorion.

This prestigious conference dedicated to biotechnologies is a major showcase that enables us to continue developing our licensing and partnerships around the world,” highlights Mealy Kong, associate director of Ciloa. His company has developed exclusive technology to detect drugs, and to develop immunotherapy and vaccines.

Celia Belline, CEO of CILcare, a leading R&D service company in the field of hearing loss, says: “We were able to organize 40 business meetings and visits with customers and partners at our Lexington office. This led to the signature of contracts, some of which will be carried out in Montpellier.


This event, which attracts biotech and pharmaceutical industry leaders from over 74 countries, is an ideal springboard for Montpellier Health Capital, an initiative driven by Montpellier Métropole to stimulate and promote the Montpellier area health ecosystem and its innovations in the medical field. Massachusetts, where the show was held this year, is the leading state in the U.S. high-tech life sciences sector.

“Our goal was to meet prospective customers to offer our services in medicinal chemistry. We moved forward with four non-disclosure agreements, which was more than I expected,” says Jean-Marc Allaire, CEO of Oxeltis, who is already making plans for the future: “We’ll be sure not to miss BIO 2019 next year in Philadelphia!

There are 0 commentaires on this page